PR-401

N/A

Report date: 2022/04/11 17:54:18

Base Information

Drug NamePR-401
Drug Alias NameClaudin 18.2 CAR-TPR-401
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsAnti-CLDN18
TargetsClaudin-18 splice variant 2
Therapy Area/IndicationsPancreatic NeoplasmsStomach Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesShandong Boan Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShandong Boan Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsPancreatic NeoplasmsStomach Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A